Kazuhiro Murai, Takahiro Kodama, Hayato Hikita, Akiyoshi Shimoda, Makoto Fukuoka, Keisuke Fukutomi, Satoshi Shigeno, Yuto Shiode, Daisuke Motooka, Yuichiro Higuchi, Kei Miyakawa, Hiroshi Suemizu, Akihide Ryo, Yuki Tahata, Yuki Makino, Ryoko Yamada, Ryotaro Sakamori, Tomohide Tatsumi, Tetsuo Takehara – 23 May 2022 – Current anti–hepatitis B virus (HBV) therapies have little effect on covalently closed circular DNA (cccDNA) and fail to eliminate HBV.

The goal of the AASLD Hepatotoxicity SIG is to promote and encourage research, education, and awareness regarding human hepatotoxicity. As such, individuals with any of the following interests and expertise are encouraged to partake in SIG activities.

The mission of the Hepatology Associates SIG is to enhance member engagement through networking, mentorship, education and career development opportunities.

The SIG is dedicated to supporting Associates in optimizing translation of evidence into best clinical practices and delivery of comprehensive patient-centered care through interdisciplinary collaboration and education to improve health outcomes across all practice settings.

This group works to promote hepatitis C elimination through disease awareness, clinical education, research and advocacy.

This group works to promote national and international collaboration to promote clinical care and research in the field of the hepatitis B virus (HBV) and to improve awareness among health care professionals and the public regarding the prevention of HBV, screening high risk populations for HBV and management of chronic HBV based on AASLD Guidelines

The goal of the Clinical Practice SIG is to promote the practice of Hepatology in a community practice setting.

The Cholestatic and Autoimmune Liver Diseases Special Interest Group (SIG) is an international community of investigators and practitioner focusing on preventing diagnosing and treating cholestatic liver diseases, as well as diseases of the biliary tree (cholangiopathies). The SIG also strongly focuses on understanding the pathophysiology and on the genetics of cholestatic and biliary diseases as a way to identify novel therapeutic targets.

Amanda P. C. S. Boteon, Andrea Schlegel, Mauricio F. Carvalho, Yuri L. Boteon – 22 May 2022

Thomas G. Cotter, Thomas Beresford – 22 May 2022

Antonio D'Alessio, Claudia Angela Maria Fulgenzi, David J. Pinato – 22 May 2022